Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 806,553
  • Shares Outstanding, K 48,882
  • Annual Sales, $ 30,430 K
  • Annual Income, $ -85,340 K
  • 60-Month Beta 2.86
  • Price/Sales 27.00
  • Price/Cash Flow N/A
  • Price/Book 2.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.53
  • Number of Estimates 7
  • High Estimate -0.47
  • Low Estimate -0.64
  • Prior Year -0.43
  • Growth Rate Est. (year over year) -23.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.01 +26.82%
on 11/18/19
17.80 -7.30%
on 12/05/19
+2.56 (+18.36%)
since 11/13/19
3-Month
10.26 +60.82%
on 10/09/19
17.80 -7.30%
on 12/05/19
+2.25 (+15.79%)
since 09/13/19
52-Week
10.26 +60.82%
on 10/09/19
19.00 -13.16%
on 08/01/19
+0.68 (+4.30%)
since 12/13/18

Most Recent Stories

More News
Gene Therapy the Next Best Thing: Here's Why (Revised)

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

NTLA : 16.50 (-1.84%)
VRTX : 218.98 (-0.71%)
QURE : 73.97 (+7.39%)
MGTX : 21.02 (+2.44%)
PIRS : 3.29 (-4.91%)
Gene Therapy the Next Best Thing: Here's Why

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

NTLA : 16.50 (-1.84%)
VRTX : 218.98 (-0.71%)
QURE : 73.97 (+7.39%)
MGTX : 21.02 (+2.44%)
PIRS : 3.29 (-4.91%)
Don't Judge a Month by its First Day

Don't Judge a Month by its First Day

UAL : 87.58 (-1.01%)
BLDR : 25.36 (+0.24%)
TGT : 127.22 (-0.24%)
KBH : 34.95 (+0.72%)
NAVI : 14.13 (+1.95%)
HPE : 16.03 (-2.26%)
BBY : 84.79 (-0.66%)
DHI : 54.81 (+0.83%)
DKS : 47.92 (-1.18%)
NWL : 19.21 (-1.18%)
SYNA : 64.00 (+7.85%)
VGR : 12.79 (+1.51%)
CRSP : 65.36 (-1.01%)
EDIT : 29.90 (-0.76%)
NTLA : 16.50 (-1.84%)
Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data

Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.

VRTX : 218.98 (-0.71%)
NTLA : 16.50 (-1.84%)
EDIT : 29.90 (-0.76%)
CRSP : 65.36 (-1.01%)
The NASDAQ Needs No Break

The NASDAQ Needs No Break

WYNN : 129.78 (-1.88%)
TAL : 45.52 (+0.26%)
CDAY : 62.51 (+1.53%)
ETSY : 42.29 (+0.74%)
MCD : 197.12 (+0.41%)
JCI : 40.44 (-3.74%)
FTNT : 105.64 (+1.19%)
URI : 162.74 (-0.28%)
SID : 3.40 (-0.29%)
ENTG : 50.01 (+0.46%)
LDOS : 91.84 (+0.71%)
MFC : 19.29 (-1.18%)
ROST : 115.49 (-0.82%)
SSW : 14.14 (+0.07%)
CRSP : 65.36 (-1.01%)
NTLA : 16.50 (-1.84%)
EDIT : 29.90 (-0.76%)
Axovant's GM1 Gangliosidosis Candidate Gets Orphan Drug Tag

The FDA grants Orphan Drug status to Axovant's (AXGT) gene therapy candidate, AXO-AAV-GM1, being developed for the treatment of GM1 gangliosidosis. Shares decline despite the positive news.

IDRA : 1.60 (-1.84%)
NTLA : 16.50 (-1.84%)
ANIK : 53.15 (-0.65%)
AXGT : 5.53 (-1.25%)
NASDAQ Hits New Record Despite Slow Session

NASDAQ Hits New Record Despite Slow Session

BA : 341.67 (-1.33%)
CMG : 815.32 (+0.51%)
TRWH : 25.20 (+1.98%)
CORE : 25.60 (-1.12%)
INXN : 80.12 (-0.53%)
WY : 29.64 (+0.30%)
BIDU : 119.14 (-1.16%)
HTHT : 36.87 (+5.89%)
WYNN : 129.78 (-1.88%)
YELP : 33.55 (+0.48%)
JD : 34.00 (+0.53%)
ESTC : 62.16 (+1.88%)
SDOW : 39.73 (-0.20%)
SQQQ : 24.45 (-0.93%)
GWPH : 106.62 (+0.87%)
NTLA : 16.50 (-1.84%)
Intellia Therapeutics, Inc. (NTLA) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Intellia Therapeutics, Inc. (NTLA).

NTLA : 16.50 (-1.84%)
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 19.67% and 16.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the...

NTLA : 16.50 (-1.84%)
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 8.20% and 44.39%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?...

NTLA : 16.50 (-1.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade NTLA with:

Business Summary

Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with...

See More

Key Turning Points

2nd Resistance Point 17.40
1st Resistance Point 16.95
Last Price 16.50
1st Support Level 16.14
2nd Support Level 15.78

See More

52-Week High 19.00
Last Price 16.50
Fibonacci 61.8% 15.66
Fibonacci 50% 14.63
Fibonacci 38.2% 13.60
52-Week Low 10.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar